Powell speech takes center stage in Tuesday’s economic events
NLS Pharmaceutics Ltd. (NASDAQ:NLSP) filed a report Thursday providing updated financial statements connected to its planned merger with Kadimastem Ltd. (TASE:KDST). The filing is based on a press release statement.
The documents submitted include Kadimastem’s unaudited interim condensed financial statements as of June 30, 2025, and audited financial statements for the years ended December 31, 2024 and 2023. In addition, NLS Pharmaceutics provided unaudited pro forma condensed combined financial statements for the six months ended June 30, 2025.
According to the previously announced merger agreement, signed November 4, 2024, Kadimastem will merge with and into NLS Pharmaceutics’ wholly owned Israeli subsidiary, with the subsidiary remaining as the surviving entity. At the effective time of the merger, each outstanding ordinary share of Kadimastem will be exchanged for a specified number of fully paid and nonassessable common shares of NLS Pharmaceutics, as determined under the terms of the agreement.
The financial statements were filed to comply with reporting obligations related to the merger process. The filing includes no further details on the closing timeline or additional transaction terms.
The company’s principal executive offices are located in Zurich, Switzerland. The filing was signed by Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics.
All information in this article is based on a statement made in a recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.